PubMed Health⌕ Search

Biomedical subjects

Timo Hakulinen

Publications and source records attributed to Timo Hakulinen.

46 records · Page 3Linked to original sources
PubMed2002

Advanced detection of time trends in long-term cancer patient survival: experience from 50 years of cancer registration in Finland.

Timely monitoring of trends in long-term patient survival is an important task of cancer registries. Recently, a new method, denoted period analysis, has been proposed to enhance up-to-date monitoring of survival. The authors assessed the use of period analysis for advanced detection of time trends in long-term cancer patient survival based on data from the nationwide Finnish Cancer Registry by comparing estimates of 10-, 15-, and 20-year relative survival rates obtained by period analysis and by traditional (cohort) analysis of survival at various points of time between 1953 and 1997. Time trends are graphically displayed for the 15 most common forms of cancer. Long-term survival rates strongly improved over time for most forms of cancer. The slope and shape of trend curves obtained by period analysis are very similar to those obtained by traditional survival analysis. However, detection of progress in 10-, 15-, and 20-year survival rates of newly diagnosed patients could have been advanced by 5-10 years, 10-15 years, and 15-20 years, respectively, with the use of period analysis rather than traditional cohort survival analysis. The authors conclude that period analysis should be routinely used to advance detection of progress in long-term cancer patient survival.

Adolescent↗
PubMed2002

Oral contraceptive use before first birth and risk of breast cancer: a case control study.

BACKGROUND: The aim of this study was first, to investigate whether women starting oral contraceptive (OC) use at a young age and before first birth have an increased risk for breast cancer and second, to report difficulties encountered in studying long-term health impacts of medical technologies. METHODS: Breast cancers occurring up until 1997 among 37153 Helsinki students born between 1946 and 1960 were identified by record linkage from the Finnish Cancer Registry; for each cancer case, five age-matched random controls were picked from the same student population. Those who had used the Helsinki Student Health Service (HSHS) at least three times (150 cases and 316 controls) form the final study subjects. Data on OC use and background characteristics were collected from patient records, and data on live births were derived from the population register. Odds ratios (OR) were adjusted for number of births, smoking and sports activity. RESULTS: Compared to the few non-users, OC users had a higher risk of breast cancer: the adjusted OR was 2.1 (95% confidence interval 1.1-4.2). Among OC users, no statistically significant differences in risk of breast cancer were found in regard to starting age or first birth, but small numbers made confidence intervals wide. Even though we had chosen students to be our study group, the population turned out to be unsuitable to answer our research question: most women had started their OC use old (at the age of 20 or later) and there were very few unexposed (almost all had used OC and before their first birth). CONCLUSIONS: Because adoption of the modern pattern of OC use was not common among students, it is unlikely that the impact of early and extended OC use can be studied before 2010, when women born in the 1960s are 40 to 50 years old.

Journal Article↗
PubMed2002

Up-to-date long-term survival curves of patients with cancer by period analysis.

PURPOSE: Provision of up-to-date long-term survival curves is an important task of cancer registries. Traditionally, survival curves have been derived for cohorts of patients diagnosed many years ago. Using data of the Finnish Cancer Registry, we provide an empirical assessment of the use of a new method of survival analysis, denoted period analysis, for deriving more up-to-date survival curves. PATIENTS AND METHODS: We calculated 10-year relative survival curves actually observed for patients diagnosed with one of the 15 most common forms of cancer in 1983 to 1987, and we compared them with the most up-to-date 10-year relative survival curves that might have been obtained in 1983 to 1987 using either traditional (cohort-wise) or period analysis. We also give the most recent 10-year survival curves obtained by period analysis for the 1993 to 1997 period. RESULTS: For all forms of cancer, period analysis of the 1983 to 1987 data yielded survival curves that were very close to the survival curves later observed for patients who were newly diagnosed in that period (median and maximum difference of 10-year relative survival estimates: 0.9 and 5.7 percent units, respectively). By contrast, the survival curves obtained by traditional (cohort-wise) survival analysis in 1983 to 1987 would have been much lower for most forms of cancer (median and maximum difference: 5.8 and 18.4 percent units, respectively). The 10-year survival curves for the 1993 to 1997 period are substantially more favorable than previously available, traditionally derived survival curves for most forms of cancer. CONCLUSION: Period analysis is a useful tool for deriving up-to-date long-term survival curves of patients with cancer.

Humans↗
PubMed2002

Relative survival of patients with prostate cancer as a first or subsequent tumor--a Nordic collaborative study.

OBJECTIVE: To present a new model for estimating relative survival of patients with two primary cancers, to study whether survival from cancer is similar between a first and subsequent tumor, and to provide an illustration of prognoses for patients with cancer as a subsequent tumor. METHODS: Data on Danish, Finnish, and Norwegian patients with a first and subsequent prostate cancer, after a first primary colorectal cancer, were analyzed with a new model. RESULTS: Survival from first and subsequent prostate cancer was similar within each country. Survival from subsequent prostate cancer was not affected by the time interval between the first colorectal and subsequent prostate cancer. CONCLUSIONS: The survival from subsequent cancer should be adjusted for the underlying first primary cancer. The overall relative survival of patients with two primary cancers will be worse than those with a respective single cancer only. However, with a proper adjustment the subsequent cancer itself is not more fatal than a similar cancer as the only tumor of the patient.

Adult↗
PubMed2002

Flavonoid intake and risk of chronic diseases.

BACKGROUND: Flavonoids are effective antioxidants and may protect against several chronic diseases. OBJECTIVE: The association between flavonoid intake and risk of several chronic diseases was studied. DESIGN: The total dietary intakes of 10 054 men and women during the year preceding the baseline examination were determined with a dietary history method. Flavonoid intakes were estimated, mainly on the basis of the flavonoid concentrations in Finnish foods. The incident cases of the diseases considered were identified from different national public health registers. RESULTS: Persons with higher quercetin intakes had lower mortality from ischemic heart disease. The relative risk (RR) between the highest and lowest quartiles was 0.79 (95% CI: 0.63, 0.99: P for trend = 0.02). The incidence of cerebrovascular disease was lower at higher kaempferol (0.70; 0.56, 0.86; P = 0.003), naringenin (0.79; 0.64, 0.98; P = 0.06), and hesperetin (0.80; 0.64, 0.99; P = 0.008) intakes. Men with higher quercetin intakes had a lower lung cancer incidence (0.42; 0.25, 0.72; P = 0.001), and men with higher myricetin intakes had a lower prostate cancer risk (0.43; 0.22, 0.86; P = 0.002). Asthma incidence was lower at higher quercetin (0.76; 0.56, 1.01; P = 0.005), naringenin (0.69; 0.50, 0.94; P = 0.06), and hesperetin (0.64; 0.46, 0.88; P = 0.03) intakes. A trend toward a reduction in risk of type 2 diabetes was associated with higher quercetin (0.81; 0.64, 1.02; P = 0.07) and myricetin (0.79; 0.62, 1.00; P = 0.07) intakes. CONCLUSION: The risk of some chronic diseases may be lower at higher dietary flavonoid intakes.

Adult↗
PubMed2002

Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland.

BACKGROUND: Providing up-to-date estimates of cancer patient survival rates is an important task of cancer registries. A few years ago, a new method of survival analysis, denoted period analysis, was proposed to enhance the recency of long-term survival estimates. The aim of this paper is to provide a comprehensive empirical evaluation of the use of this method. METHODS: Using data from the nationwide Finnish Cancer Registry, we compare 5-year and 10-year relative survival rates of 371 849 patients diagnosed with one of the 16 most common forms of cancer in Finland at various time intervals between 1953 and 1992 with the most up-to-date estimates of 5-year or 10-year relative survival that might have been obtained in those time intervals by traditional methods of survival analysis and by period analysis of survival. RESULTS: Survival rates strongly increased over time for most forms of cancer. For these cancers, traditional estimates of 5- and 10-year survival rates would have severely lagged behind the survival rates later observed for newly diagnosed patients, and period analysis would consistently have provided much more up-to-date estimates of survival rates. CONCLUSIONS: We conclude that period analysis should be implemented as a standard tool for providing up-to-date estimates of long-term survival rates by cancer registries.

Aged↗